JP2011529691A - 腫瘍動態を評価するための循環変異型ｄｎａ - Google Patents

腫瘍動態を評価するための循環変異型ｄｎａ Download PDF

Info

Publication number
JP2011529691A
JP2011529691A JP2011521359A JP2011521359A JP2011529691A JP 2011529691 A JP2011529691 A JP 2011529691A JP 2011521359 A JP2011521359 A JP 2011521359A JP 2011521359 A JP2011521359 A JP 2011521359A JP 2011529691 A JP2011529691 A JP 2011529691A
Authority
JP
Japan
Prior art keywords
dna
mutation
tumor
gene
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011521359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529691A5 (https=
Inventor
フランク ディール
ルイス ディアス
ケネス ダブリュ． キンズラー
バート ヴォゲルステイン
カースティン シュミット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41610753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011529691(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2011529691A publication Critical patent/JP2011529691A/ja
Publication of JP2011529691A5 publication Critical patent/JP2011529691A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/197—Modifications characterised by incorporating a spacer/coupling moiety
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/131—Allele specific probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2549/00—Reactions characterised by the features used to influence the efficiency or specificity
    • C12Q2549/10—Reactions characterised by the features used to influence the efficiency or specificity the purpose being that of reducing false positive or false negative signals
    • C12Q2549/119—Reactions characterised by the features used to influence the efficiency or specificity the purpose being that of reducing false positive or false negative signals using nested primers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2011521359A 2008-07-31 2009-07-31 腫瘍動態を評価するための循環変異型ｄｎａ Pending JP2011529691A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8517508P 2008-07-31 2008-07-31
US61/085,175 2008-07-31
US12/512,585 2009-07-30
US12/512,585 US20100041048A1 (en) 2008-07-31 2009-07-30 Circulating Mutant DNA to Assess Tumor Dynamics
PCT/US2009/052436 WO2010014920A1 (en) 2008-07-31 2009-07-31 Circulating mutant dna to assess tumor dynamics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015231649A Division JP2016104010A (ja) 2008-07-31 2015-11-27 腫瘍動態を評価するための循環変異型ｄｎａ

Publications (2)

Publication Number Publication Date
JP2011529691A true JP2011529691A (ja) 2011-12-15
JP2011529691A5 JP2011529691A5 (https=) 2012-08-30

Family

ID=41610753

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011521359A Pending JP2011529691A (ja) 2008-07-31 2009-07-31 腫瘍動態を評価するための循環変異型ｄｎａ
JP2015231649A Pending JP2016104010A (ja) 2008-07-31 2015-11-27 腫瘍動態を評価するための循環変異型ｄｎａ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015231649A Pending JP2016104010A (ja) 2008-07-31 2015-11-27 腫瘍動態を評価するための循環変異型ｄｎａ

Country Status (5)

Country Link
US (4) US20100041048A1 (https=)
EP (1) EP2315849B1 (https=)
JP (2) JP2011529691A (https=)
CA (1) CA2732623C (https=)
WO (1) WO2010014920A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016060227A1 (ja) * 2014-10-17 2016-04-21 東洋鋼鈑株式会社 Ｂｃｒ－ａｂｌ阻害剤耐性関連変異の検出方法及びこれを用いたｂｃｒ－ａｂｌ阻害剤耐性を予測するためのデータ取得方法
JP2016104010A (ja) * 2008-07-31 2016-06-09 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍動態を評価するための循環変異型ｄｎａ
WO2017014177A1 (ja) * 2015-07-17 2017-01-26 凸版印刷株式会社 健康状態の評価方法及び抗がん剤に対する長期奏功性の予測方法
JP2018522550A (ja) * 2015-06-23 2018-08-16 ナショナル キャンサー センター 導電性高分子を利用したセルフリーｄｎａ検出用構造体およびその用途
WO2020026776A1 (ja) 2018-07-31 2020-02-06 学校法人 岩手医科大学 がんの診断のためのプローブ／プライマーライブラリー
JP2024516150A (ja) * 2021-04-22 2024-04-12 ナテラ， インコーポレイテッド 腫瘍成長の速度を決定するための方法
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1712639B1 (en) 2005-04-06 2008-08-27 Maurice Stroun Method for the diagnosis of cancer by detecting circulating DNA and RNA
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
WO2010028288A2 (en) 2008-09-05 2010-03-11 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
EP2376659B1 (en) 2008-12-17 2015-12-02 Life Technologies Corporation Methods, compositions, and kits for detecting allelic variants
EP2411543B1 (en) 2009-03-27 2017-04-19 Life Technologies Corporation Methods, compositions, and kits for detecting allelic variants
WO2011103236A2 (en) * 2010-02-18 2011-08-25 The Johns Hopkins University Personalized tumor biomarkers
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12545960B2 (en) 2010-05-18 2026-02-10 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
WO2011146632A1 (en) 2010-05-18 2011-11-24 Gene Security Network Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
EP2619329B1 (en) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
CN105243295B (zh) 2010-11-30 2018-08-17 香港中文大学 与癌症相关的遗传或分子畸变的检测
CN103608466B (zh) 2010-12-22 2020-09-18 纳特拉公司 非侵入性产前亲子鉴定方法
RU2671980C2 (ru) 2011-02-09 2018-11-08 Натера, Инк. Способы неинвазивного пренатального установления плоидности
ES2986436T3 (es) 2011-04-15 2024-11-11 Univ Johns Hopkins Sistema de secuenciación segura
JP2013081450A (ja) * 2011-09-27 2013-05-09 Arkray Inc 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用試薬キット
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
WO2013123442A1 (en) * 2012-02-17 2013-08-22 Fred Hutchinson Cancer Research Center Compositions and methods for accurately identifying mutations
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
WO2014004726A1 (en) * 2012-06-26 2014-01-03 Caifu Chen Methods, compositions and kits for the diagnosis, prognosis and monitoring of cancer
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
CN104781421B (zh) 2012-09-04 2020-06-05 夸登特健康公司 检测稀有突变和拷贝数变异的系统和方法
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
JP6200511B2 (ja) 2012-10-26 2017-09-20 シスメックス株式会社 エマルジョン系及びエマルジョンベースの核酸増幅
ES2886507T5 (es) 2012-10-29 2024-11-15 Univ Johns Hopkins Prueba de Papanicolaou para cánceres de ovario y de endometrio
ES2662598T3 (es) 2013-03-08 2018-04-09 F. Hoffmann-La Roche Ag Análisis de sangre para la detección de mutaciones de EGFR
US20140287417A1 (en) 2013-03-08 2014-09-25 Roche Molecular Systems, Inc. EGFR Blood Monitoring
WO2014151117A1 (en) 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
EP3611262B1 (en) 2013-03-15 2020-11-11 Lineage Biosciences, Inc. Methods of sequencing the immune repertoire
US9898575B2 (en) 2013-08-21 2018-02-20 Seven Bridges Genomics Inc. Methods and systems for aligning sequences
US9116866B2 (en) 2013-08-21 2015-08-25 Seven Bridges Genomics Inc. Methods and systems for detecting sequence variants
US11049587B2 (en) 2013-10-18 2021-06-29 Seven Bridges Genomics Inc. Methods and systems for aligning sequences in the presence of repeating elements
SG11201603039PA (en) 2013-10-18 2016-05-30 Seven Bridges Genomics Inc Methods and systems for identifying disease-induced mutations
KR20160062763A (ko) 2013-10-18 2016-06-02 세븐 브릿지스 지노믹스 인크. 유전자 샘플을 유전자형 결정하기 위한 방법 및 시스템
WO2015058095A1 (en) 2013-10-18 2015-04-23 Seven Bridges Genomics Inc. Methods and systems for quantifying sequence alignment
HK1222209A1 (zh) * 2013-10-19 2017-06-23 Trovagene, Inc. 隨時間檢測疾病中的突變
US9092402B2 (en) 2013-10-21 2015-07-28 Seven Bridges Genomics Inc. Systems and methods for using paired-end data in directed acyclic structure
ES2660989T3 (es) 2013-12-28 2018-03-27 Guardant Health, Inc. Métodos y sistemas para detectar variantes genéticas
US9817944B2 (en) 2014-02-11 2017-11-14 Seven Bridges Genomics Inc. Systems and methods for analyzing sequence data
US12492429B2 (en) 2014-04-21 2025-12-09 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
CA2945962C (en) 2014-04-21 2023-08-29 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US20160002717A1 (en) * 2014-07-02 2016-01-07 Boreal Genomics, Inc. Determining mutation burden in circulating cell-free nucleic acid and associated risk of disease
EP4358097A1 (en) 2014-07-25 2024-04-24 University of Washington Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
DK3198026T3 (da) * 2014-08-07 2020-01-20 Pharmassist Ltd Fremgangsmåde til bestemmelse af pik3ca-mutationsstatus i en prøve
US12391985B2 (en) 2014-08-07 2025-08-19 Pharmassist Ltd Method of determining PIK3CA mutational status in a sample
CN107075730A (zh) 2014-09-12 2017-08-18 利兰·斯坦福青年大学托管委员会 循环核酸的鉴定及用途
HUE058263T2 (hu) 2015-02-10 2022-07-28 Univ Hong Kong Chinese Mutációk detektálása rákszûrési és magzatelemzési célból
WO2016141294A1 (en) 2015-03-05 2016-09-09 Seven Bridges Genomics Inc. Systems and methods for genomic pattern analysis
CN104762399A (zh) * 2015-04-17 2015-07-08 上海产业技术研究院 肿瘤循环dna kras突变检测方法
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
US10793895B2 (en) 2015-08-24 2020-10-06 Seven Bridges Genomics Inc. Systems and methods for epigenetic analysis
US10584380B2 (en) 2015-09-01 2020-03-10 Seven Bridges Genomics Inc. Systems and methods for mitochondrial analysis
US10724110B2 (en) 2015-09-01 2020-07-28 Seven Bridges Genomics Inc. Systems and methods for analyzing viral nucleic acids
JP6991134B2 (ja) * 2015-10-09 2022-01-12 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａを使用する集団ベースの処置レコメンダ
US11347704B2 (en) 2015-10-16 2022-05-31 Seven Bridges Genomics Inc. Biological graph or sequence serialization
EP3611274A1 (en) * 2015-11-20 2020-02-19 QIAGEN GmbH Method for processing a water-in-oil emulsion
SG11201805119QA (en) 2015-12-17 2018-07-30 Guardant Health Inc Methods to determine tumor gene copy number by analysis of cell-free dna
US20170199960A1 (en) 2016-01-07 2017-07-13 Seven Bridges Genomics Inc. Systems and methods for adaptive local alignment for graph genomes
US10364468B2 (en) 2016-01-13 2019-07-30 Seven Bridges Genomics Inc. Systems and methods for analyzing circulating tumor DNA
JP6685138B2 (ja) 2016-01-27 2020-04-22 シスメックス株式会社 核酸増幅の精度管理方法、精度管理用試薬およびその試薬キット
US10262102B2 (en) 2016-02-24 2019-04-16 Seven Bridges Genomics Inc. Systems and methods for genotyping with graph reference
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
US10790044B2 (en) 2016-05-19 2020-09-29 Seven Bridges Genomics Inc. Systems and methods for sequence encoding, storage, and compression
US11289177B2 (en) 2016-08-08 2022-03-29 Seven Bridges Genomics, Inc. Computer method and system of identifying genomic mutations using graph-based local assembly
US11250931B2 (en) 2016-09-01 2022-02-15 Seven Bridges Genomics Inc. Systems and methods for detecting recombination
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
WO2018090298A2 (en) * 2016-11-17 2018-05-24 Genomicare Biotechnology (Shanghai) Co. Ltd. Systems and methods for monitoring lifelong tumor evolution
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US20180334398A1 (en) * 2017-01-25 2018-11-22 Qiagen Gmbh Method for processing a water-in-oil emulsion
SG11201906397UA (en) 2017-01-25 2019-08-27 Univ Hong Kong Chinese Diagnostic applications using nucleic acid fragments
JP6933907B2 (ja) 2017-02-24 2021-09-08 シスメックス株式会社 核酸増幅方法
US10726110B2 (en) 2017-03-01 2020-07-28 Seven Bridges Genomics, Inc. Watermarking for data security in bioinformatic sequence analysis
US11347844B2 (en) 2017-03-01 2022-05-31 Seven Bridges Genomics, Inc. Data security in bioinformatic sequence analysis
WO2018183942A1 (en) 2017-03-31 2018-10-04 Grail, Inc. Improved library preparation and use thereof for sequencing-based error correction and/or variant identification
US10527608B2 (en) 2017-06-13 2020-01-07 Genetics Research, Llc Methods for rare event detection
US10081829B1 (en) 2017-06-13 2018-09-25 Genetics Research, Llc Detection of targeted sequence regions
US10947599B2 (en) 2017-06-13 2021-03-16 Genetics Research, Llc Tumor mutation burden
EP3638812A4 (en) * 2017-06-13 2021-04-28 Genetics Research, LLC, D/B/A ZS Genetics, Inc. DETECTION OF RARE NUCLEIC ACIDS
US11142788B2 (en) 2017-06-13 2021-10-12 Genetics Research, Llc Isolation of target nucleic acids
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
CN111051536A (zh) 2017-07-26 2020-04-21 香港中文大学 利用不含细胞的病毒核酸改善癌症筛选
CN111868260B (zh) 2017-08-07 2025-02-21 约翰斯霍普金斯大学 用于评估和治疗癌症的方法和材料
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12046325B2 (en) 2018-02-14 2024-07-23 Seven Bridges Genomics Inc. System and method for sequence identification in reassembly variant calling
US12398389B2 (en) 2018-02-15 2025-08-26 Natera, Inc. Methods for isolating nucleic acids with size selection
WO2019162941A1 (en) * 2018-02-21 2019-08-29 Nucleix Ltd. Methods and kits for determining the efficiency of plasma separation from whole blood
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US20210054465A1 (en) * 2018-05-03 2021-02-25 Roche Sequencing Solutions, Inc. Surrogate marker and method for tumor mutation burden measurement
US11702697B2 (en) * 2018-05-14 2023-07-18 Roche Sequencing Solutions, Inc. Quality testing of DNA samples
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
EP3725894A1 (en) * 2019-04-16 2020-10-21 Blod Diagnostik GmbH Apparatus and methods for nucleic acid target enrichment, suspension and quantification
US12305235B2 (en) 2019-06-06 2025-05-20 Natera, Inc. Methods for detecting immune cell DNA and monitoring immune system
EP3983431A4 (en) * 2019-06-17 2023-12-13 The Board of Trustees of the Leland Stanford Junior University Diagnostics and treatments based upon molecular characterization of colorectal cancer
US20230028621A1 (en) 2019-12-23 2023-01-26 Biopsense Oy Method, automated system and cartridge for extraction of cell-free nucleic acids from a blood sample
EP4103748A4 (en) 2020-02-14 2024-03-13 The Johns Hopkins University METHOD AND MATERIALS FOR ASSESSING NUCLEIC ACIDS
CN111575377B (zh) * 2020-05-19 2024-02-23 邹畅 用于line-1的检测引物组及其应用
WO2022031620A2 (en) * 2020-08-01 2022-02-10 Aigene Methods for the rapid assessment of the efficacy of cancer therapy and related applications
US20220275450A1 (en) * 2021-02-24 2022-09-01 Michael J. Powell Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence
WO2024211551A1 (en) 2023-04-06 2024-10-10 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
WO2025213054A1 (en) * 2024-04-05 2025-10-09 Board Of Regents, The University Of Texas System Inhibition of csf-1 or csf-1r for the treatment of minimal residual disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522229A (ja) * 2002-04-09 2005-07-28 オックスフォード グライコサイエンシス （ユーケイ） リミテッド 癌に関与する蛋白質
WO2006128192A2 (en) * 2005-05-27 2006-11-30 John Wayne Cancer Institute Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
JP2007277242A (ja) * 2006-04-05 2007-10-25 Pfizer Prod Inc Ｃｔｌａ４抗体併用療法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2324997A (en) * 1996-03-15 1997-10-01 Penn State Research Foundation, The Detection of extracellular tumor-associated nucleic acid in blood plasma or ser um using nucleic acid amplification assays
US20020120409A1 (en) * 2000-05-19 2002-08-29 Affymetrix, Inc. Methods for gene expression analysis
US20030165940A1 (en) * 2001-12-06 2003-09-04 The Johns Hopkins University Disease detection by digital protein truncation assays
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
ES2381204T3 (es) * 2005-10-24 2012-05-24 The Johns Hopkins University Métodos mejorados para BEAMING
US20100041048A1 (en) * 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
US8517508B2 (en) 2009-07-02 2013-08-27 Fujifilm Dimatix, Inc. Positioning jetting assemblies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522229A (ja) * 2002-04-09 2005-07-28 オックスフォード グライコサイエンシス （ユーケイ） リミテッド 癌に関与する蛋白質
WO2006128192A2 (en) * 2005-05-27 2006-11-30 John Wayne Cancer Institute Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
JP2007277242A (ja) * 2006-04-05 2007-10-25 Pfizer Prod Inc Ｃｔｌａ４抗体併用療法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014007977; Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ．　２００８　Ａｕｇ（Ｅｐｕｂ　２００８　Ｍａｙ　１５），　Ｖｏｌ．１３５，　Ｎｏ．２，　ｐ．４８９-４９８，４９８ｅ１-４９８ｅ７ *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016104010A (ja) * 2008-07-31 2016-06-09 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍動態を評価するための循環変異型ｄｎａ
WO2016060227A1 (ja) * 2014-10-17 2016-04-21 東洋鋼鈑株式会社 Ｂｃｒ－ａｂｌ阻害剤耐性関連変異の検出方法及びこれを用いたｂｃｒ－ａｂｌ阻害剤耐性を予測するためのデータ取得方法
JP2016077221A (ja) * 2014-10-17 2016-05-16 東洋鋼鈑株式会社 Ｂｃｒ−ａｂｌ阻害剤耐性関連変異の検出方法及びこれを用いたｂｃｒ−ａｂｌ阻害剤耐性を予測するためのデータ取得方法
JP2018522550A (ja) * 2015-06-23 2018-08-16 ナショナル キャンサー センター 導電性高分子を利用したセルフリーｄｎａ検出用構造体およびその用途
US11352616B2 (en) 2015-06-23 2022-06-07 National Cancer Center Nanostructure for detecting cell-free DNA using conductive polymer and the use thereof
WO2017014177A1 (ja) * 2015-07-17 2017-01-26 凸版印刷株式会社 健康状態の評価方法及び抗がん剤に対する長期奏功性の予測方法
JPWO2017014177A1 (ja) * 2015-07-17 2018-04-26 凸版印刷株式会社 健康状態の評価方法及び抗がん剤に対する長期奏功性の予測方法
WO2020026776A1 (ja) 2018-07-31 2020-02-06 学校法人 岩手医科大学 がんの診断のためのプローブ／プライマーライブラリー
KR20210038607A (ko) 2018-07-31 2021-04-07 이와테 메디칼 유니버시티 에듀케이셔널 파운데이션 암의 진단을 위한 프로브/프라이머 라이브러리
US12492433B2 (en) 2018-07-31 2025-12-09 Iwate Medical University Educational Foundation Probe/primer library for diagnosis of cancer
JP2024516150A (ja) * 2021-04-22 2024-04-12 ナテラ， インコーポレイテッド 腫瘍成長の速度を決定するための方法
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法

Also Published As

Publication number Publication date
US20250313901A1 (en) 2025-10-09
EP2315849B1 (en) 2017-11-08
CA2732623C (en) 2018-08-21
WO2010014920A1 (en) 2010-02-04
JP2016104010A (ja) 2016-06-09
EP2315849A4 (en) 2012-02-22
US20100041048A1 (en) 2010-02-18
US20200370123A1 (en) 2020-11-26
US20240002948A1 (en) 2024-01-04
EP2315849A1 (en) 2011-05-04
CA2732623A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
US20250313901A1 (en) Circulating mutant dna to assess tumor dynamics
JP7385630B2 (ja) 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法
Rose et al. Circulating and urinary tumour DNA in urothelial carcinoma—upper tract, lower tract and metastatic disease
US9109256B2 (en) Method for monitoring disease progression or recurrence
CN113981057B (zh) 用于进行甲基化检测测定的组合物和方法
JP4808365B2 (ja) Ｐｃｒ法
CA2957396C (en) Method of determining pik3ca mutational status in a sample
JP2011529691A5 (https=)
Polivka Jr et al. Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?
JP7665659B2 (ja) 循環腫瘍核酸分子のマルチモーダル分析
WO2009051842A2 (en) Detection of cancer by measuring genomic copy number and strand length in cell-free dna
TW201326481A (zh) 預測易罹患卵巢贅瘤或卵巢癌預後之生物標記
JP2010518868A (ja) 前立腺癌の生存及び再発
ES3036448T3 (en) A dna-methylation test for prostate cancer
US12391985B2 (en) Method of determining PIK3CA mutational status in a sample
JP6608424B2 (ja) 前癌性結腸直腸ポリープおよび結腸直腸癌を特定するための方法およびキット
US20250179583A1 (en) Methylated dna markers and assays thereof for use in detecting colorectal cancer
TW202328459A (zh) 一種腫瘤檢測方法及應用
JP2011015679A (ja) 黒色腫の早期検出のための方法及び試薬
US20070248546A1 (en) Clinical algorithm for excluding patients identified in virtual imaging
JP2014527816A (ja) 初期卵巣がんの検出マーカーとしての精子タンパク質
KR20220052466A (ko) Braf 유전자 내의 단일염기다형성 마커를 포함하는 대장암 재발 예측용 조성물
KR20220052467A (ko) Egfr 유전자 내의 단일염기다형성 마커를 포함하는 대장암 재발 예측용 조성물
Colin et al. Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells
BR122020011728B1 (pt) Método para detectar pelo menos uma mutação em uma pluralidade de genes relacionados a câncer de tireoide, para selecionar um sujeito que tem nódulos na tireoide com citologia indeterminada para cirurgia diagnóstica, e para prognosticar risco de malignidade em um sujeito com resultados de citologia para paaf da tireoide inconclusivos, e, kit para detectar pelo menos uma mutação em genes relacionados ao câncer de tireoide em uma amostra ffpe da tireoide ou uma amostra paaf da tireoide, e para detectar pelo menos um produto de fusão genética em uma amostra ffpe da tireoide ou uma amostra paaf da tireoide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140530

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150304

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160115